Piper Jaffray Cos. upgraded shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) from a neutral rating to an overweight rating in a report issued on Monday morning.

SRPT has been the subject of a number of other reports. Leerink Swann reiterated an underperform rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, August 4th. Vetr cut shares of Sarepta Therapeutics from a hold rating to a sell rating and set a $17.28 price objective for the company. in a report on Monday, May 23rd. Robert W. Baird reiterated an outperform rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a report on Monday, July 18th. Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, July 26th. Finally, JMP Securities reiterated an underperform rating and issued a $10.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, September 15th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $48.70.

Sarepta Therapeutics (NASDAQ:SRPT) opened at 60.97 on Monday. The firm’s market capitalization is $2.92 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $61.60. The company has a 50-day moving average price of $30.01 and a 200-day moving average price of $21.91.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter last year, the firm posted ($0.87) EPS. On average, equities research analysts predict that Sarepta Therapeutics will post ($4.17) earnings per share for the current fiscal year.

In other news, SVP David T. Howton sold 9,304 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $465,200.00. Following the completion of the transaction, the senior vice president now owns 11,168 shares of the company’s stock, valued at $558,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $651,000. Eagle Asset Management Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $6,756,000. Amici Capital LLC bought a new position in shares of Sarepta Therapeutics during the first quarter worth approximately $488,000. LGL Partners LLC raised its position in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new position in shares of Sarepta Therapeutics during the first quarter worth approximately $7,461,000. 72.09% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.